- Home
- FCEL vs CNTX Comparison
FCEL vs CNTX Comparison
Compare FCEL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- CNTX
- Stock Information
- Founded
- FCEL 1969
- CNTX 2015
- Country
- FCEL United States
- CNTX United States
- Employees
- FCEL N/A
- CNTX N/A
- Industry
- FCEL Industrial Machinery/Components
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- FCEL Energy
- CNTX Health Care
- Exchange
- FCEL Nasdaq
- CNTX Nasdaq
- Market Cap
- FCEL 96.7M
- CNTX 78.0M
- IPO Year
- FCEL 1992
- CNTX 2021
- Fundamental
- Price
- FCEL $4.12
- CNTX $0.71
- Analyst Decision
- FCEL Hold
- CNTX Strong Buy
- Analyst Count
- FCEL 6
- CNTX 6
- Target Price
- FCEL $14.28
- CNTX $6.50
- AVG Volume (30 Days)
- FCEL 745.4K
- CNTX 98.8K
- Earning Date
- FCEL 06-09-2025
- CNTX 05-07-2025
- Dividend Yield
- FCEL N/A
- CNTX N/A
- EPS Growth
- FCEL N/A
- CNTX N/A
- EPS
- FCEL N/A
- CNTX N/A
- Revenue
- FCEL $114,438,000.00
- CNTX N/A
- Revenue This Year
- FCEL $42.70
- CNTX N/A
- Revenue Next Year
- FCEL $10.61
- CNTX N/A
- P/E Ratio
- FCEL N/A
- CNTX N/A
- Revenue Growth
- FCEL 11.09
- CNTX N/A
- 52 Week Low
- FCEL $3.58
- CNTX $0.55
- 52 Week High
- FCEL $30.90
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- FCEL 47.18
- CNTX 38.67
- Support Level
- FCEL $3.89
- CNTX $0.74
- Resistance Level
- FCEL $4.75
- CNTX $0.85
- Average True Range (ATR)
- FCEL 0.29
- CNTX 0.08
- MACD
- FCEL 0.07
- CNTX -0.02
- Stochastic Oscillator
- FCEL 46.15
- CNTX 4.88
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.